Case Studies

2025-08-25

Anti-HE4 Antibody: Cancer Diagnosis Breakthrough | AtaGenix

A 2017 study developed a high-affinity anti-HE4 monoclonal antibody (9C3) using AtaGenix’s advanced mammalian expression and hybridoma platforms. This breakthrough enhances ovarian cancer diagnostics by targeting the HE4 biomarker with high specificity, offering potential for early detection and therapy.

2025-08-25

SARS-CoV-2 Spike Peptides: 2021 Breakthrough in Neutralizing Antibody Research

This article highlights a 2021 Small Methods study that identified immunogenic peptides in the SARS-CoV-2 spike protein and isolated neutralizing monoclonal antibodies from COVID-19 patients. The research pinpointed key RBM epitopes (S431-454, S470-486, S501-515), with S470-486 emerging as an immunodominant target for diagnostics and therapeutics. Using phage display and ScFv libraries, the study validated epitope mapping and antibody functionality. Supported by AtaGenix’s expertise in phage display, protein expression, and assay development, this breakthrough offers a scalable approach for combating emerging viral pathogens, updated as of August 24, 2025.

2025-08-24

Shrimp MANF: Anti-Inflammatory Breakthrough | AtaGenix

This article explores a 2022 peer-reviewed study published in The Journal of Immunology, revealing that Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) in Litopenaeus vannamei (shrimp) acts as a conserved anti-inflammatory factor. The research demonstrates that extracellular MANF suppresses ERK phosphorylation and downregulates Dorsal (NF-κB) via a receptor-type tyrosine phosphatase (RPTP) in hemocytes, highlighting an ancient immune regulation mechanism with implications for neuroprotection, metabolism, and aging. Cross-species validation in human 293T cells further confirms MANF’s conserved role. Supported by AtaGenix, the study utilized advanced techniques including plasma proteomics, qPCR, and sandwich ELISA with phage display-generated monoclonal antibodies. This breakthrough, detailed as of August 24, 2025, underscores AtaGenix’s role in accelerating innate immunity research through custom antibody discovery, protein expression, and assay development.

2025-08-25

AtaGenix Empowers Research on Shrimp Plasma MANF's Anti-Inflammatory Role via Conserved Receptor Tyrosine Phosphatase

This study experimentally identifies shrimp plasma mesencephalic astrocyte-derived neurotrophic factor (MANF) as an LPS-induced protein that inhibits ERK phosphorylation and Dorsal expression in Litopenaeus vannamei hemocytes, elucidating its inflammation regulation mechanism via a conserved receptor tyrosine phosphatase (RPTP). AtaGenix supports the development of high-affinity antibodies, advancing research progress and providing new insights into the evolution of inflammation in invertebrates.

2025-08-20

AtaGenix Customized Phosphorylated Polyclonal Antibodies Unveil the Role of SLKv in Cancer Glycolysis

This pioneering study leverages AtaGenix customized phosphorylated polyclonal antibodies to explore the critical role of the alternatively spliced variant of Ste20-like kinase (SLKv) in enhancing cancer glycolysis and tumor progression. Researchers demonstrated that SLKv boosts enolase 1 (ENO1) activity by binding and phosphorylating its serine 2 residue, significantly increasing phosphoenolpyruvate (PEP) production. This metabolic shift accelerates glycolysis by activating key enzymes such as hexokinase 2 (HK2), phosphofructokinase muscle (PFKM), and phosphoglycerate mutase 1 (PGAM1), with TGFβ-mediated splicing factor KHDRBS1 driving SLK exon skipping. The precision of AtaGenix’s phospho-specific ENO1-S2 antibody enabled accurate quantification of phosphorylation levels, enhancing the study’s reliability. Targeting SLKv with antisense oligonucleotides effectively inhibits glycolysis and tumor growth, marking it as a promising metabolic target for cancer therapy.

2025-08-04

AtaGenix’s Customized ATG8 Antibody Solutions for Studying Amino Acid Metabolism Reprogramming in BmNPV-Infected Silkworms

Bombyx mori nucleopolyhedrovirus (BmNPV) significantly impacts sericulture by reprogramming host amino acid metabolism to support viral replication. AtaGenix provides tailored solutions, including high-specificity ATG8 polyclonal antibodies, to address research challenges in studying BmNPV-induced autophagy and arginine metabolism. These antibodies, validated through immunofluorescence and Western Blot, ensure reliable detection of autophagy markers, aiding researchers in uncovering the virus’s metabolic regulation mechanisms. Supported by advanced gene editing and analytical techniques, our services empower research teams to advance antiviral strategies with agricultural applications.

2025-07-14

AtaGenix’s Custom Phospho-USP8 Antibody Advances MDA5 Homeostasis Research, Unveiling a Novel Target for Autoimmune Therapy

A research team from the Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital revealed that phosphorylation of USP8 at Ser718 by AKT regulates the stability of MDA5, a key player in innate antiviral immunity and autoimmune responses. To investigate this mechanism, AtaGenix developed a custom rabbit antibody targeting the phosphorylated Ser718 site on USP8. This high-specificity antibody enabled the team to detect dynamic USP8 activation in cells, confirming its role in MDA5 regulation. The study, published in Advanced Science, provides a new perspective for targeting USP8–MDA5 signaling in autoimmune disease therapy.

2025-06-20

AtaGenix Provides Custom CHALK10 and SD1 Protein Expression and Rabbit Polyclonal Antibody Services for Rice Chalkiness Research at China National Rice Research Institute

AtaGenix Laboratories Co., Ltd. partnered with the State Key Laboratory of Rice Biology and Breeding, China National Rice Research Institute, to provide custom protein expression and rabbit polyclonal antibody production services for a rice chalkiness study published in Plant Communications (DOI: 10.1016/j.xplc.2025.101354). The study identified CHALK10, an F-box protein, as a negative regulator of grain chalkiness by promoting the ubiquitination and degradation of SEMIDWARF-1 (SD1). AtaGenix expressed CHALK10 and SD1 proteins in Escherichia coli Rosetta (DE3) cells, purified them using affinity chromatography, and produced specific rabbit polyclonal antibodies. Validated through co-immunoprecipitation (co-IP) assays, these reagents supported the study’s findings on CHALK10’s role in regulating gibberellin-mediated starch metabolism, advancing rice grain quality research.

2025-06-20

AtaGenix Delivers Custom Rabbit Polyclonal Antibody Services for Haojie Hao’s Team at Wuhan Institute of Virology

AtaGenix Laboratories Co., Ltd. collaborated with the research team led by Haojie Hao at the Wuhan Institute of Virology to develop a custom mouse polyclonal antibody (pAb) against the Nipah virus (NiV) M protein, supporting a groundbreaking study published in Viruses (DOI: 10.3390/v17060831, IF: 3.8 Q2). The study revealed the critical role of N6-methyladenosine (m6A) modification in enhancing NiV replication and pathogenicity, particularly in the NiV-Malaysia strain. By designing specific antigens and delivering high-titer pAbs validated through Western blot assays in biosafety level 4 (BSL-4) conditions, AtaGenix enabled the team to confirm the M protein’s role in modulating host m6A machinery, advancing antiviral research.

2024-11-05

Antibody Fragment Production

Using AtaGenix's mammalian cell expression system, various antibody fragments have been successfully expressed, including scFv, VHH, Fab, and scFv-Fc-scFv, meeting diverse research and development needs.The accompanying images demonstrate the expression results and workflow of antibody production using this advanced system.

2024-11-05

Large-Scale Recombinant Antibody Production

Using AtaGenix's proprietary XtenCHO™ mammalian expression system, full-length IgG, VHH, scFv, and Fab antibody fragments were successfully expressed. The accompanying SDS-PAGE analysis demonstrates the system's ability to produce high-quality proteins:

2024-11-05

Chimeric Antibody Expression and Validation | AtaGenix Custom Antibody Development Services

Chimeric antibody production combines the variable region of one species with the constant region of another to achieve optimal specificity and functionality. This approach ensures high binding affinity while maintaining robust stability and compatibility with downstream applications. Utilizing cutting-edge expression systems, production is scalable, cost-effective, and delivers high-purity antibodies suitable for therapeutic and research purposes.